| Document |
Document Title |
|
WO/2013/091282A1 |
Provided are cajanine structure analogous compounds, synthesis method and pharmacological effects thereof, the compounds of the present invention having the structure as represented by general formulas I, II, III, IV and V. Also provided...
|
|
WO/2013/073815A1 |
The present invention relates to the synthesis of 2,2'-dihydroxy-1,1'-binaphthyl-3-carboxylic acid or a derivative thereof by reacting 2-hydroxynaphthalene or a derivative thereof and 3-hydroxy-2-naphthalene carboxylic acid or a derivati...
|
|
WO/2013/021944A9 |
The present invention provides a complex in which metal nanoparticles are included in a porous coordination polymer (PCP), wherein the PCP is configured from a metal ion and an organic ligand.
|
|
WO/2013/014660A1 |
Compounds particularly for use in an autoimmune inflammatory disease and especially the treatment of inflammatory bowel disease have the formula: wherein R is selected from one or more of the same or different of hydrogen, hydroxyl, opti...
|
|
WO/2013/014659A1 |
Described are compounds of the structural formula (I): Also provided are pharmacologically acceptable isomers and salts of the compound of (I). The compounds are useful in the treatment of inflammatory bowel disease.
|
|
WO/2013/000669A1 |
Fragrances having a fresh scent are usually very volatile and therefore not very economical in typical applications, such as washing or cleaning processes. Thus, said fragrances must be used in relatively large quantities, in order to br...
|
|
WO/2012/167530A1 |
The present invention relates to a cleaning agent for a lubricating oil and the production process thereof, and a process method for producing an additive for a lubricating oil having a TBN of from about 100 to about 400, the process met...
|
|
WO/2012/155368A1 |
A method for preparing 2, 5-dihydroxyterephthalic acid is provided. The raw material of 1, 4-dihalo-2, 5-dialkoxybenzene is converted to 2, 5-dialkoxyterephthalic acid via Grignard carboxylation, and 2, 5-dialkoxyterephthalic acid underg...
|
|
WO/2012/117968A1 |
The problem addressed by the present invention is to provide a method for controlling the genesis and/or differentiation of an embryo by easily and rapidly controlling the obstruction of activation of the Wnt signal without using a genet...
|
|
WO/2012/077673A1 |
Provided is a method for efficiently producing 4,5-dialkoxy-2-hydroxybenzoic acid from low-cost starting materials. Specifically provided is a method for producing 2-bromo-4,5-dialkoxy benzoic acid represented by general formula (2) (whe...
|
|
WO/2012/066366A1 |
The invention relates to non-sulfonic acid type new rasagiline salts, a process for the preparation thereof, pharmaceutical compositions containing said salts and the use thereof for the treatment or prophylaxis of various diseases, name...
|
|
WO/2012/060451A1 |
The invention provides a composition containing a chelating agent and un-heated cashew nutshell oil.
|
|
WO/2012/055014A1 |
Phenylketone carboxylate compounds of Formula I, wherein n=2-6; R=C(0); -OC(O)- or -CH( OH)-; A is (CH2)mCOOH, W(CH2)mCOOH or YCH(COOH)((CH2)pCH3) when B is Ft B is (CH2)mCOOH, W(CH2)mCOOH or YCH(COOH)((CH2)pCH3) when A is Ft or A snd B ...
|
|
WO/2012/011112A1 |
The present invention provides dihydro-CBD compounds of formula (I) and derivatives thereof, compositions comprising them and uses thereof in the manufacture of medicaments for the treatment of conditions, diseases, disorders or symptoms...
|
|
WO/2011/160821A2 |
The present invention refers to joint mixtures of phenylbutyric acid or its ions and at least one organic molecule, like organic salts of phenylbutyrate, polymorphs, hydrates or solvates thereof and co-crystals of phenylbutyric acid and ...
|
|
WO/2011/162351A1 |
The disclosed porous metal complex comprises a metal complex formed by the coordinate bonding of a trivalent metal ion with an aromatic tricarboxylic acid represented by formula (1). The porous metal complex has a microporous structure f...
|
|
WO/2011/148520A1 |
Provided is a dispersant for non-aqueous dispersion media that can be used for a broad range of substances to be dispersed and which can exhibit excellent dispersion stability with small amounts added. The dispersant for non-aqueous disp...
|
|
WO/2011/148660A1 |
Provided is a dispersant for non-aqueous dispersion media that can be used for a broad range of substances to be dispersed and which can exhibit excellent dispersion stability with small amounts added. The dispersant for non-aqueous disp...
|
|
WO/2011/136513A2 |
Provided is a bone-transplant or bone-filling composition, which comprises a dihydroxybenzoic acid derivative which has been newly demonstrated to increase the activity of osteoblasts and so induce bone formation.
|
|
WO/2011/128431A1 |
Disclosed are novel cross-linkable end-cappers for oligo-and polyimides. End-capped oligo-and polyimides comprising such an end-capper may be cured at a lower temperature compared to oligo-and polyimides end-capped with PEPA.
|
|
WO/2011/105521A1 |
Disclosed is a metal complex having high adsorption properties, high gas occlusion properties and high gas separation properties. The general formula (I) is below; 【Chemical Formula 1】(in the formula, R1-R4 are as set forth in the de...
|
|
WO/2011/089529A1 |
Fatty acid conjugates of salicylate derivatives and compositions thereof are disclosed. Further disclosed are methods for treating and/or preventing an inflammatory disease including inflammation and/or inflammatory bowel disease (IBD), ...
|
|
WO/2011/089874A1 |
In order to provide a highly pure 1:2 clathrate of an aromatic carboxylic acid compound and an imidazole compound, and to provide an epoxy resin composition containing said clathrate as a curing agent or a curing promoter, it is possible...
|
|
WO/2011/084726A1 |
A compound of formula: Pharmaceutical compositions containing the compound, and methods of inducing cytokine biosynthesis in an animal, treating a viral infection and/or treating a neoplastic disease in an animal by administering an effe...
|
|
WO/2011/084725A1 |
A compound of formula:[ I ] Pharmaceutical compositions containing the compound, and methods of inducing cytokine biosynthesis in an animal, treating a viral infection and/or treating a neoplastic disease in an animal by administering an...
|
|
WO/2011/037929A2 |
Pd (II) -catalyzed ortho-hydroxylat ion of variously substituted aromatic carboxylic acids under O2 or air is achieved under non-acidic conditions. Extensive labeling studies support a direct oxygenation of aryl C-H bonds with molecular ...
|
|
WO/2011/028852A2 |
Fluorinated ethers of aromatic acids are produced from halogenated aromatic acids in a reaction mixture containing a copper (I) or copper (II) source and an amino acid ligand that coordinates to copper. The fluorinated ethers of aromatic...
|
|
WO/2011/028866A2 |
Fluorinated ethers of aromatic acids are produced from halogenated aromatic acids in a reaction mixture containing a copper (I) or copper (II) source and a diketone ligand that coordinates to copper. The fluorinated ethers of aromatic ac...
|
|
WO/2011/028872A2 |
Fluorinated ethers of aromatic acids are produced from halogenated aromatic acids in a reaction mixture containing a copper (I) or copper (II) source and a diamine ligand that coordinates to copper. The fluorinated ethers of aromatic aci...
|
|
WO/2011/028851A2 |
New fluorinated ethers of aromatic acids and diesters are disclosed. These compositions can be applied to, e.g., fibers, yarns, carpets, garments, films, molded parts, paper and cardboard, stone, and tile to impart soil, water and oil re...
|
|
WO/2011/028862A2 |
Fluorinated ethers of aromatic acids are produced from halogenated aromatic acids in a reaction mixture containing a copper (I) or copper (II) source and a Schiff base ligand that coordinates to copper. The fluorinated ethers of aromatic...
|
|
WO/2011/007146A1 |
Compounds of formula (I) are suitable for use as herbicides: wherein R is methyl, ethyl, vinyl, ethynyl or cyclopropyl, R1 is hydrogen, C1-C6alkyl, C1-C6haloalkyl, C3-C7cycloalkyl, C1-C6alkoxy, C1-C6haloalkoxy, vinyl, propenyl, ethynyl, ...
|
|
WO/2010/115252A9 |
The present invention relates to phthalimide derivatives of non-steroidal anti-inflammatory compounds and/or TNF-α modulators, to a method for producing these derivatives, to pharmaceutical compositions containing these derivatives, and...
|
|
WO/2010/145800A1 |
The present invention relates to tramadol-diflunisal salts, processes for preparation of the same and their uses as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain.
|
|
WO/2010/144959A1 |
The present invention relates to analogues of anti-fibrotic agents having the formula (I) with the substituents as described within the specification. The present invention also relates to methods for their preparation.
|
|
WO/2010/142124A1 |
Medicines with adamantane structure and their derivatives and analogues having new activity and indications such as antitumor, and their uses as medicine for treating some diseases such as tumor. The medicines are the compounds having th...
|
|
WO/2010/139481A1 |
The invention relates to naphthalene derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are glycine B antagonis...
|
|
WO/2010/141334A1 |
A process for synthesis of a compound of Formula (X) wherein R1 is an aryl group substituted with one to three substituent groups, wherein each substituent group of R1 is independently C1-C5 alkyl, aminocarbonyl, alkylaminocarbonyl, dial...
|
|
WO/2010/137943A1 |
The present invention discloses a composition comprising caffeoylshikimic acids, protocatechuic acid, hydroxytyrosol, hydroxybenzoic acid, said caffeoylshikimic acids and their derivatives extracted from any part of oil palm including bu...
|
|
WO/2010/134477A1 |
Disclosed is a radiation-sensitive resin composition containing (A) an acid-dissociable group-containing resin and (C) a compound represented by general formula (1). In general formula (1), Z- represents a monovalent anion represented by...
|
|
WO/2009/120215A9 |
A method for preparing an oxydiphthalic anhydride comprises contacting, under reactive and substantially anhydrous conditions in a reactor, at least one halophthalic anhydride containing more than 250 ppm chlorophthalide impurity with a ...
|
|
WO/2010/116099A1 |
The invention relates to a method for preparing molecular complexes between Adapalene and cyclodextrins using the technology of dense fluids under pressure, especially that of CO2.
|
|
WO/2010/117108A1 |
The present invention relates to a polyacetylene supramolecular sieve having selectivity for cationic or anionic compounds, and a chemical sensor for detecting cationic or anionic compounds using the same, and more specifically, the poly...
|
|
WO/2010/094554A1 |
The invention relates to an improved method for releasing an organic acid, preferably a carbon, sulfone or phosphone acid, particularly an alpha or beta hydroxycarbon acid, from the ammonia salt thereof by releasing and removing ammoniac...
|
|
WO/2010/094630A1 |
The invention relates to a method for converting ammonium salts of organic acids into the respective free organic acids, wherein an aqueous solution of the ammonium salt is brought into contact with an organic extraction agent, and the s...
|
|
WO/2010/067622A1 |
Disclosed are compounds of 90% or higher purity and that are represented by only one or the other of formula (1) or formula (2), and compositions comprising compound (1) and compound (2) wherein the molar ratio of compound (1):compound (...
|
|
WO/2010/067627A1 |
A compound represented by R-X, wherein R is a group represented by formula (1) and X is a halogen atom, hydroxy, an aryloxy, or a (meth)acrylic ester group represented by formula (5).
|
|
WO/2010/043584A1 |
The invention relates to the use of and mainly novel compounds of the formula (I) wherein the moieties are as defined in the description, which are useful as farnesyl pyrophosphate synthase modulators and e.g. in the treatment of prolife...
|
|
WO/2010/041748A1 |
Disclosed is a prophylactic or therapeutic agent for diabetes, diabetic complications, insulin resistance syndrome, metabolic syndrome, hyperglycemia, dyslipidemia, atherosclerosis, heart failure, cardiomyopathy, myocardial ischemia, cer...
|
|
WO/2010/035561A1 |
Disclosed is a gas adsorbing material having a three-dimensional structure. The three-dimensional structure comprises an aromatic ring as a main skeleton. A ligand (p-hydroxybenzoic acid) containing a carboxyl group and a functional gr...
|
